Other manufacturing industries

iHeart Japan Corporation

iHeart Japan Corporation

We are developing a regenerative medicine product for heart failure. The product consists of cardiac cell sheets and biomaterials. We have the technology to efficiently produce cardiomyocytes and vascular endothelial cells from iPS cells. Furthermore, we also have a cell sheet lamination technology using gelatin hydrogel microspheres, which enables us to manufacture multi-layered cardiac cell sheet. We named the product as IHJ-301.
We have almost completed pre-clinical studies of IHJ-301 and we expect that we can get permission to initiate the clinical trial of IHJ-301 within 1 year.
Area of Interest
  • North America
  • Europe
  • Southeast Asia
  • China

Site-visit

Not allowed


SDGs we are working on
3.Good health and well-being 5.Gender equality 8.Decent work and economic growth 16.Peace, justice and strong institutions

Registered Keyword
We are developing a regenerative medicine product for heart failure. The product consists of cardiac cell sheets and biomaterials. We have the technology to efficiently produce cardiomyocytes and vascular endothelial cells from iPS cells. Furthermore, we also have a cell sheet lamination technology using gelatin hydrogel microspheres, which enables us to manufacture multi-layered cardiac cell sheet. We named the product as IHJ-301.
We have almost completed pre-clinical studies of IHJ-301 and we expect that we can get permission to initiate the clinical trial of IHJ-301 within 1 year.

Concept of a regenerative medicine product(IHJ-301) for heart failure